Introduction Anticoagulation may improve outcomes in patients with COVID-19 when started
early in the course of illness. Materials and methods This was a population-based cohort …

Venous thromboembolism (VTE) is common in patients with coronavirus disease-2019
(COVID-19). The optimal heparin regimen remains unknown and should balance …

Background Randomised controlled trials (RCTs) have reported inconsistent effects from
intensified anticoagulation on clinical outcomes in Covid-19. We performed an aggregate …

Patients with COVID-19 may complicate their evolution with thromboembolic events.
Incidence of thromboembolic complications are high and also, patients with the critically-ill …

Purpose The optimal amount of anticoagulation for critically ill COVID-19 patients is
controversial. Therefore, we aimed to evaluate the efficacy and safety of escalated doses of …

Abstract Background Coronavirus disease (COVID-19) is a global health emergency, with
well over six hundred million infections and over six million deaths to date. Besides other …

Background Previous studies demonstrate a reduced risk of thrombosis and mortality with
anticoagulant treatment in patients with COVID-19 than in those without anticoagulation …

Coagulopathies are common in intensive therapy units (ITUs) and may represent both the
cause and the consequence of a critically ill status. Because coagulopathies are associated …

1448 Point and Counterpoint[161# 6 CHEST JUNE 2022] propensity to activate clotting
cascade within afflicted patients. Specifically, initial reports identified VTE in as many as …

The prevalence of venous thromboembolism is high in patients with COVID-19, despite
prophylactic anticoagulation. The evidence that supports the preferred thromboprophylaxis …